Rosuvastatin vs Lovastatin

## Overview

Rosuvastatin and lovastatin represent the widest potency gap compared in these statin pairs. Rosuvastatin is the most potent statin available; lovastatin is one of the least potent. Their metabolic profiles are also markedly different.

## Mechanism of Action

Both inhibit HMG-CoA reductase. Rosuvastatin binds in the active hydroxy acid form; lovastatin is a prodrug lactone requiring hydrolysis. Rosuvastatin's binding affinity is exceptionally high (IC50 in the picomolar range).

## Pharmacokinetics

Rosuvastatin: bioavailability 20%, half-life 19 h, minimal CYP2C9 metabolism. Lovastatin: bioavailability 5%, half-life 2–3 h, complete CYP3A4 dependence, food effect significant. These differences translate to very different drug interaction profiles.

## Pharmacodynamics

Rosuvastatin 10–40 mg achieves 46–55% LDL-C reduction. Lovastatin at maximum dose (80 mg) achieves ~40% — equivalent to rosuvastatin 5–10 mg. For ACC/AHA high-intensity therapy, rosuvastatin is appropriate; lovastatin falls short at any dose.

## Clinical Considerations

Lovastatin's natural origin (fungal fermentation) historically gave it an early-mover advantage. Its use has declined sharply as potent synthetic statins became generic. Rosuvastatin became generic in many markets around 2016, largely eliminating cost as a differentiator.

## Key Takeaways

- Rosuvastatin is 8–10× more potent per mg than lovastatin
- Lovastatin requires food; rosuvastatin does not
- Rosuvastatin: CYP2C9 substrate (minor); Lovastatin: CYP3A4 (major)
- Lovastatin no longer preferred in guidelines for high-risk patients